Placebo-controlled Study of Methotrexate in Juvenile Localised Scleroderma PDF Print E-mail
Wednesday, 09 February 2011 16:24
According to the results of this placebo-controlled study, methotrexate is an effective treatment for juvenile localised scleroderma (JLS).

The authors note that JLS is a chronic progressive fibrotic process of the skin causing permanent disability and aesthetic damage.  There is deep tissue involvement, and around 20% will have another organ involved.  Although it is the most common form of scleroderma in children, it remains poorly understood.  There is no universally accepted treatment for this condition; however methotrexate (MTX) has been reported to be beneficial.   

In this study, they randomised 70 patients aged 6-17 years with active JLS to receive double-blind treatment with methotrexate (15mg/m2; max 20mg; n=46) or placebo (n=24) once weekly, alongside oral prednisolone (1mg/kg/day; max 50mg) for the initial three months (followed by one month of dose tapering).  Treatment was continued for 12 months, or until treatment failure, if sooner.  Patients were assessed during six clinical visits throughout the treatment period.  The primary endpoint was the rate of response to treatment at the end of the 12 month period.  Response was defined as no new lesions, a skin score rate (SSR) score of a target lesion <1, and a decrease in lesion temperature by at least 10% compared to baseline.

Around half of the enrolled patients completed the 12-month study, including 67.4% of the MTX group and 29.2% of the placebo group (premature discontinuation due to disease flare in all cases).  All 70 enrolled patients were included in the intention-to-treat analysis of efficacy.  The main findings were as follows:

• At the final visit, 67.4% of the MTX group and 29.2% of the placebo-treated patients had responded to treatment (p=0.001).
• After an initial response, disease relapsed in 15 MTX patients (32.6%) and 17 placebo (70.8%) (p<0.005).
• The likelihood to experience a flare of disease in the MTX group was around one third of that in the placebo group (hazard ratio [HR] 2.82, 95% CI 1.40 - 5.66).
• New lesions appeared in three MTX patients (6.5%) vs. four of those on placebo (16.7%), mean SSR decreased from 1 to 0.79 with MTX vs. 1.1 on placebo (p=0.011), and the mean target lesion temperature decreased by 44.4% vs. 12.1%, respectively (p=0.024)

The authors conclude that methotrexate in combination with a short course of prednisone is beneficial and well tolerated as a treatment for localised scleroderma in children.

Source: Pocock, N. (2011), "Placebo-controlled Study of Methotrexate in Juvenile Localised Scleroderma"; taken from original article here.
 
More articles :

» Caution Needed When Using ACE Inhibitors in Scleroderma

Exposure to angiotensin-converting enzyme inhibitors prior to the onset of renal crisis in patients with increases the risk of death, according to 1-year findings from the prospective observational International Scleroderma Renal Crisis Survey.The...

» Important Information About Autoimmune Diseases

There are more than 100 known autoimmune disorders, including rheumatoid arthritis, type 1 diabetes, scleroderma, and lupus. Normally, your immune system is designed to protect your health. But in some people, the immune system creates...

» A Perspective on Juvenile Systemic Sclerosis

Juvenile systemic sclerosis is one of the most serious rheumatologic diseases diagnosed in children and adolescents, according to Dr. Ivan Foeldvari. This complex disorder is characterized by fibrosis of the skin, subcutaneous tissues, and internal...

» A New Marker of Silent Cardiovascular Disease in Diffuse Scleroderma

Patients with diffuse systemic sclerosis (SSc) and no clinical evidence of (CVD) may, in fact, have subclinical CVD and , and it is detectable. This is the conclusion of a small pilot study from Italy, which showed that elevated plasma levels of ...

» African Americans Have More Severe Complications From Scleroderma

African Americans have more severe complications from systemic sclerosis, also known as scleroderma, than Caucasians. Findings published today in, , a journal of the American College of Rheumatology (ACR), show that compared with Caucasians,...

» Management

Our Management Team or Executive Committee is presently responsible for the daily operations of the Scleroderma Care Foundation, realizing its vision, and similarly ensuring its growth and future success. Adelwyn Holder, Co-Founder &...